Earnings Call Summary | Phibro Animal Health(PAHC.US) Q3 2024 Earnings Conference
Earnings Call Summary | Phibro Animal Health(PAHC.US) Q3 2024 Earnings Conference
The following is a summary of the Phibro Animal Health Corporation (PAHC) Q3 2024 Earnings Call Transcript:
以下是Phibro動物健康公司（PAHC）2024年第三季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Phibro Animal Health Corporation reported Q3 2024 net sales of $263.2 million, representing a 7% increase from the same quarter a year prior.
The company saw different performance across its segments with net sales in the Animal Health segment increasing by 10%, a meager 2% growth in Mineral Nutrition, while Performance Products experienced a decline.
Adjusted EBITDA saw an increment of $2.3 million due to improved numbers in the Animal Health and Mineral Nutrition sectors.
The firm recorded 9% rises in both adjusted net income and adjusted diluted earnings per share (EPS).
The Animal Health division was the star performer this quarter with double-digit growth in the top line.
Phibro動物健康公司報告稱，2024年第三季度淨銷售額爲2.632億美元，比去年同期增長7％。
該公司各細分市場的表現各不相同，動物健康板塊的淨銷售額增長了10％，礦物質營養板塊僅增長了2％，而高性能產品則出現了下降。
由於動物健康和礦物營養領域的數字有所改善，調整後的息稅折舊攤銷前利潤增長了230萬美元。
該公司的調整後淨收益和調整後的攤薄後每股收益（EPS）均增長了9％。
動物健康部門是本季度表現最好的部門，收入增長了兩位數。
Business Progress:
業務進展：
The company is geared up for integrating new colleagues and products from Phibro following its acquisition of Zoetis' medicated feed additive portfolio.
The Zoetis acquisition is expected to increase Phibro's product diversity, species offerings, and also bolster its earnings along with facilitating debt repayment.
Phibro is optimistic about sustained growth in its Animal Health business and improvements in the Mineral Nutrition and Performance Products businesses.
The company reaffirms its initial guidance concerning net sales, adjusted EBITDA, and adjusted diluted earnings per share.
在收購了Zoetis的藥用飼料添加劑產品組合後，該公司正準備整合Phibro的新同事和新產品。
對Zoetis的收購預計將增加Phibro的產品多樣性和物種供應，並增加其收益，同時促進債務償還。
Phibro對其動物健康業務的持續增長以及礦物營養和高性能產品業務的改善持樂觀態度。
該公司重申了其有關淨銷售額、調整後息稅折舊攤銷前利潤和調整後的攤薄後每股收益的初步指導方針。
More details: Phibro Animal Health IR
更多詳情： Phibro 動物健康 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。